Abstract
Objectives: To describe the efficacy and tolerability of switching to raltegravir (RAL) in virologically suppressed HIV-1-infected patients during routine clinical practice.
Methods: A total number of 263 subjects (189 men, median age 48.1 years) with HIV-1 RNA < 50 copies/mL for ≥ 6 months were switched to RAL (400 mg b.i.d). Reasons for change were toxicity (49.0%), drug interactions (6.1%) or convenience (28.6%) (switch from subcutaneous to oral treatment 22.4%, improvement of posology 3.4%). Patients were followed up to 24 months after switching to RAL. Primary end-points were tolerability and virological failure defined as two consecutive measures of HIV-1 RNA > 50 copies/mL.
Results: After a median of 12.4 months (range 2.8-26.4 months), virological failure was observed in 6 (2.3%) patients (2.2 per 100 person-years [95%CI 0.9-4.6]), while AIDS occurred in 1, drug discontinuation in 4, 3 patients died and 10 were lost to follow-up. The median CD4+ T cell count increased from 460 cells/mm3 to 508.6 cells/mm3 (P < 0.001).
Conclusions: Switching to RAL in clinical practice was mainly driven by toxicity, convenience or interactions, they were well tolerated and secured virologic suppression in the vast majority of patients.
Keywords: Raltegravir, simplification strategy, HIV infection, toxicity, CD4+, T cell, patients, lipid, virological, suppression
Current HIV Research
Title:Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive Study
Volume: 10 Issue: 8
Author(s): Vicente Estrada, The TORAL Study Group, Manuel Castano, Jorge Carmena, Antonio Antela, Josefa Galindo, Esteban Ribera, Joaquin Portilla, Ferran Segura, Eugenia Negredo, Daniel Podzamczer, Hernando Knobel, Ignacio Santos, Antonio Ocampo, Maria-Jesus Perez-Elias, Jordi Curto, Pompeyo Viciana, Elena Ferrer, Pere Domingo and Esteban Martinez
Affiliation:
Keywords: Raltegravir, simplification strategy, HIV infection, toxicity, CD4+, T cell, patients, lipid, virological, suppression
Abstract: Objectives: To describe the efficacy and tolerability of switching to raltegravir (RAL) in virologically suppressed HIV-1-infected patients during routine clinical practice.
Methods: A total number of 263 subjects (189 men, median age 48.1 years) with HIV-1 RNA < 50 copies/mL for ≥ 6 months were switched to RAL (400 mg b.i.d). Reasons for change were toxicity (49.0%), drug interactions (6.1%) or convenience (28.6%) (switch from subcutaneous to oral treatment 22.4%, improvement of posology 3.4%). Patients were followed up to 24 months after switching to RAL. Primary end-points were tolerability and virological failure defined as two consecutive measures of HIV-1 RNA > 50 copies/mL.
Results: After a median of 12.4 months (range 2.8-26.4 months), virological failure was observed in 6 (2.3%) patients (2.2 per 100 person-years [95%CI 0.9-4.6]), while AIDS occurred in 1, drug discontinuation in 4, 3 patients died and 10 were lost to follow-up. The median CD4+ T cell count increased from 460 cells/mm3 to 508.6 cells/mm3 (P < 0.001).
Conclusions: Switching to RAL in clinical practice was mainly driven by toxicity, convenience or interactions, they were well tolerated and secured virologic suppression in the vast majority of patients.
Export Options
About this article
Cite this article as:
Estrada Vicente, TORAL Study Group The, Castano Manuel, Carmena Jorge, Antela Antonio, Galindo Josefa, Ribera Esteban, Portilla Joaquin, Segura Ferran, Negredo Eugenia, Podzamczer Daniel, Knobel Hernando, Santos Ignacio, Ocampo Antonio, Perez-Elias Maria-Jesus, Curto Jordi, Viciana Pompeyo, Ferrer Elena, Domingo Pere and Martinez Esteban, Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive Study, Current HIV Research 2012; 10 (8) . https://dx.doi.org/10.2174/157016212803901428
DOI https://dx.doi.org/10.2174/157016212803901428 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mitochondria-Targeted Drugs
Current Molecular Pharmacology A Systematic Review of the Uterine Relaxant Effect of Potassium Channel Openers
Current Drug Discovery Technologies Soy Isoflavones and Cardiovascular Health: An Update
Current Nutrition & Food Science NMR Assignment and Secondary Structure of Coiled Coil Domain of C-terminal Myosin Binding Subunit of Myosin Phosphatase
Protein & Peptide Letters Axitinib in the Treatment of Head and Neck Malignancies
Current Clinical Pharmacology Complications of the Type 2 Diabetes Mellitus
Current Cardiology Reviews Cannabinoids
Current Drug Targets - CNS & Neurological Disorders Increased Arterial Stiffness is Associated with Poor Collaterals in Acute Ischemic Stroke from Large Vessel Occlusion
Current Neurovascular Research A Safe and Novel Desensitization Protocol with Ferric Carboxymaltose to Treat Iron Deficiency Anemia
Current Drug Safety Meet Our Editor:
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Autophagy Inhibition Rescues Against Leptin-Induced Cardiac Contractile Dysfunction
Current Pharmaceutical Design Dietary Intake of 3 Year Old Children: Do they Meet Recommended Intake?
Current Pediatric Reviews Incretins Yesterday, Pleiotropic Gastrointestinal Hormones Today:Glucagon-Like Peptide-1 (GLP-1) and Glucose-ependent Insulinotropic Polypeptide (GIP)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Genetic and Environmental Risk Factors in Hyperuricaemia and Common Gout
Current Rheumatology Reviews COPD Evaluation: Beyond the Airway Obstruction, a Follow Up
Current Respiratory Medicine Reviews Oxidative Stress as a Key Signaling Pathway in Placental Angiogenesis Changes in Preeclampsia: Updates in Pathogenesis, Novel Biomarkers and Therapeutics
Current Pharmacogenomics and Personalized Medicine Heart Failure in Minority Populations - Impediments to Optimal Treatment in Australian Aborigines
Current Cardiology Reviews Functional Renal MRI
Current Medical Imaging Large Artery Stiffness and Antihypertensive Agents
Current Pharmaceutical Design Analytical Techniques for the Estimation of Perindopril Erbumine: A Review
Current Pharmaceutical Analysis